Post-traumatic survival of sensory neurons of different subpopulations.
Immunohistochemical studies were performed to address the expression of the high-molecular-weight component of the neurofilament triplet NF200 (a marker of neurons forming A fibers) and the binding of isolectin B4 (IB4) by neurons of the L4-5 spinal ganglia after ligation or section of the sciatic nerve in rats. A total of 15% of neurons in the ganglia of intact rats expressed NF200. By 90 days after nerve ligation, the proportion of NF200+ neurons decreased two-fold; administration to these rats of the nerve regeneration stimulator xymedone increased the number of NF200+ neurons by 50.7% compared with controls (ligation, no treatment). In intact rats, 23.6% of neurons bound IB4. The proportion decreased by 2.6% 30 days after nerve ligation and to undetectable levels by 90 days; xymedone increased the proportion of surviving IB(4)+ neurons more than eight-fold. IB(4)+ neurons were more likely to enter post-traumatic apoptosis. Ligation of the nerve was followed by survival of fewer NF200+ and IB(4)+ neurons than section of the nerve, which suggests that axon lengthening is a factor maintaining neuron survival. The pyrimidine derivative xymedone increased the survival of neurons of both subpopulations, especially IB(4)+ neurons.
Raginov
I S
IS
Department of Histology, Cytology, and Embryology, Kazan' State Medical University.
Chelyshev
Yu A
YA
D000818:Animals; D001930:Brain Injuries / Q000473:pathology*; D002452:Cell Count / Q000379:methods; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D005727:Ganglia, Spinal / Q000473:pathology*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D006023:Glycoproteins / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D007155:Immunologic Factors / Q000627:therapeutic use; D037102:Lectins / Q000378:metabolism; D008026:Ligation / Q000379:methods; D008297:Male; D009416:Nerve Regeneration / Q000187:drug effects; D016900:Neurofilament Proteins / Q000378:metabolism; D009475:Neurons, Afferent / Q000378:metabolism / Q000502:physiology*; D011744:Pyrimidinones / Q000627:therapeutic use; D051381:Rats; D020426:Sciatic Neuropathy / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D013997:Time Factors; D053675:Versicans
D006023:Glycoproteins; D007155:Immunologic Factors; D037102:Lectins; D016900:Neurofilament Proteins; D011744:Pyrimidinones; C508324:Vcan protein, rat; C051774:neurofilament protein H; D053675:Versicans
Acta Neuropathol. 1998 Aug;96(2):191-201
9705136
Neuroreport. 2001 Dec 4;12 (17 ):3693-5
11726776
Nature. 2000 Jan 20;403(6767):312-6
10659850
Neuroscience. 1990;39(3):733-42
2097525
Neuron. 1997 Oct;19(4):849-61
9354331
J Neurocytol. 1990 Oct;19(5):789-801
2077115
Neuroscience. 1998 Jan;82(2):545-58
9466460
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):18-26
11687273
Neuroscience. 1982 Jan;7(1):89-97
6176904
Exp Brain Res. 1992;91(1):61-72
1301374
Neuroreport. 1996 Mar 22;7(4):857-60
8724660
Morfologiia. 2000;118(6):36-40
11210458
J Neurobiol. 1992 Jul;23(5):521-36
1431835
J Neurophysiol. 2000 Nov;84(5):2365-79
11067979
J Comp Neurol. 2000 Jun 26;422(2):172-80
10842225